In particular, CTLA-4 inhibition has been associated with an increase in T cell factor-1 (TCF-1)+ memory progenitor CD8+ T cells, which are crucial for sustained anti-tumor immune surveillance and preventing relapse [99–101] (Fig. 5). This evidence concerns the gene CD8A and neoplasm.